Laurent Pharmaceuticals Receives Health Canada’s Approval to Initiate Phase 2/3 Clinical Trial in Long COVID

Written By Sondra Pierson

Laurent Pharmaceuticals Inc., a Montreal-based biopharmaceutical company, today announced that it has obtained the approval from Health Canada to initiate ESSOR, an adaptive Phase 2/3 randomized placebo-controlled trial testing its oral drug candidate LAU-7b as a potential treatment for Long COVID. For the full story click here.

Sondra Pierson
Previous

NODAR Introduces GridDetect for Enhanced Road Safety in Autonomous Vehicles
Next

Senzime has entered into an agreement to acquire the US company Respiratory Motion